Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX
ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.
Yesterday 10:58 PM
360 DigiTech: A Leader in an Oscillating Market
Jun 25, 2022 10:00 AM